Browse by author
Lookup NU author(s): Professor Alan Calvert
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Throughout the history of cancer chemotherapy, the control of drug-related toxicity has been a major concern. Antifolates such as methotrexate also have a reputation for sporadic and unpredictable toxicity. Pre-treatment levels of plasma or red cell folate have not been found to be useful in predicting which patients will develop toxicity. During the phase II development of pemetrexed, the plasma levels of homocysteine and methylmalonic acid were studied as sensitive surrogate markers for folate and vitamin B12 status, respectively. These were found to be strongly correlated with the subsequent development of serious drug-related toxicities (myelosuppression, diarrhea, mucosal toxicity, and infection), suggesting that toxicity was related to relative folate deficiency in some cancer patients. A policy of nutritional supplementation was introduced and led to a marked reduction in toxicity and the abolition of treatment-related deaths with apparent preservation of anticancer activity. Copyright 2002, Elsevier Science (USA). All rights reserved.
Author(s): Calvert, A. H.
Publication type: Review
Publication status: Published
Journal: Seminars in Oncology
Year: 2002
Volume: 29
Issue: 2 supplement 5
Pages: 3-7
Print publication date: 01/04/2002
ISSN (print): 0093-7754
ISSN (electronic): 1532-8708
URL: http://www.seminoncol.org/article/S0093-7754(02)70209-1/abstract
PubMed id: 12023786
